Oculis to Present Recent Progress in its Portfolio at Upcoming Investor Conferences

...

24 November, 2020

Oculis appoints David Jacobs, M.D. as Chief Development Officer

22 October, 2020

Oculis announces presentation of OCS-01 Phase 2 DME study at EURETINA 2020

05 October, 2020

Oculis to present recent milestones at key biotech and ophthalmology conferences

22 September, 2020

Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer

01 September, 2020

Oculis to Present at the Upcoming 2020 Summer Private Company Showcase

10 August, 2020

Oculis to Present at the LifeSci Partners Private Company Virtual Summer Symposium

30 July, 2020

Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01

27 July, 2020

Oculis to Present at the Upcoming Virtual European Biotech Investor Day 2020

23 June, 2020

Oculis Reports Positive Top-line Data from SKYGGN (Phase 2) Trial with OCS-01

18 May, 2020